Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD

• Published in: Blood advances 2023-09, Vol.7 (17), p.4886-4902
• Main Authors: Buxbaum, Nataliya P., Socié, Gerard, Hill, Geoffrey R., MacDonald, Kelli P.A., Tkachev, Victor, Teshima, Takanori, Lee, Stephanie J., Ritz, Jerome, Sarantopoulos, Stefanie, Luznik, Leo, Zeng, Defu, Paczesny, Sophie, Martin, Paul J., Pavletic, Steven Z., Schultz, Kirk R., Blazar, Bruce R.
• Format: Article
• Language: English
• Subjects: Biology; Bronchiolitis Obliterans Syndrome; Consensus; Graft vs Host Disease - drug therapy; Graft vs Host Disease - therapy; Humans; Precision Medicine; Review
• ISSN: 2473-9529; 2473-9537; 2473-9537
• DOI: 10.1182/bloodadvances.2022007611

Chronic GvHD (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of non-relapse mortality and significant morbidity. Tremendous progress has been achieved in both understanding of pathophysiology and the development of new therapies for cGvHD. While our field has historically approached treatment from an empiric position, research performed at the bedside and bench has elucidated some of the complex pathophysiology of cGvHD. From the clinical perspective, there is significant variability of disease manifestations between individual patients, pointing to diverse biological underpinnings. Capitalizing on progress made to date, the field is now focused on establishing personalized treatment approaches. The manuscript’s intent is to concisely review recent knowledge gained and formulate a path towards patient-specific cGvHD therapy.